Results of Operations and Financial Condition. On July 30, 2026, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securi…

Results of Operations and Financial Condition. On May 5, 2026, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securiti…

Other Events. On April 30, 2026, the Company announced topline data from its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain. This Phase 1b, randomized, double-blind, placebo-controlled, 4-week, crossover trial enrolled 43 patients (23 chronic osteoarthritic pain (“COAP”) patients and 20 chronic low back pain (“CLBP”) patients). More information on this trial can be found at https://clinicaltrials.gov (NCT06810245). Safety and Tolerability The trial met its primary objective of assessing…

Other Events. As previously reported, on May 14, 2025, the Company entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), pursuant to which the Company may from time to time issue and sell through Leerink Partners, acting as the Company’s agent, up to $75,000,000 of shares of the Company’s Class A common stock, par value $0.001 per share (“Common Stock”), offered pursuant to the Company’s prospectus supplement, dated May 23, 2025 (the “Prior Pro…

Results of Operations and Financial Condition. On March 5, 2026, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Se…

The filing describes a new equity incentive plan for inducement grants, which is not related to any management change.

Entry into a Material Definitive Agreement. On December 11, 2025, Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Leerink Partners LLC, acting as representatives of the several underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 7,346,938 shares (the “Shares”) of the Company’s Class A common stock, par value $0.001 per share (t…

Other Events. On December 8, 2025, the Company submitted the details of its global Phase 2 clinical trial of PIPE-791 to treat patients with idiopathic pulmonary fibrosis (IPF) to the ClinicalTrials.gov Protocol Registration and Results System (PRS). These trial details will be posted at https://clinicaltrials.gov upon approval by PRS. The trial is a 26-week, international, randomized, dose-ranging, double-blind, placebo-controlled Phase 2 clinical trial evaluating once-daily dosing of PIPE-7…

Results of Operations and Financial Condition. On October 30, 2025, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the…

Other Events. On September 18, 2025, the Company announced topline data from its Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791. This Phase 1b, open label, single-center trial was designed to assess the correlation between pharmacokinetics (PK) and lysophosphatidic acid 1 (LPA1) receptor occupancy using PET imaging in healthy volunteers, as well as idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS) patients. 12 healthy volunteers and four PrMS patient…

Results of Operations and Financial Condition. On August 5, 2025, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Secur…

Results of Operations and Financial Condition. On March 6, 2025, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Se…

Results of Operations and Financial Condition. On November 6, 2024, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing, among other items, the Company’s financial results for the quarter ended September 30, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to b…

Results of Operations and Financial Condition. On August 13, 2024, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing, among other items, the Company’s financial results for the quarter ended June 30, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “fil…

Results of Operations and Financial Condition. On August 13, 2024, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing, among other items, the Company’s financial results for the quarter ended June 30, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “fil…

The filing describes the adoption of a severance plan and participation agreements for named executive officers, which is an administrative matter.

Results of Operations and Financial Condition. On May 16, 2024, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing, among other items, the Company’s financial results for the quarter ended March 31, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed…